NRLPA:OHLT

RPT Amazon launches virtual healthcare clinic in U.S. for common ailments

November 15 (Reuters) – Amazon.com Inc. (AMZN.O) on Tuesday launched the Amazon Clinic, a virtual platform where users can connect with healthcare providers to help treat common conditions such as allergies and skin conditions. Amazon has been looking for years to expand its presence in the healthcare sector, where it is a small player. He …

RPT Amazon launches virtual healthcare clinic in U.S. for common ailments Read More »

CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims

Nov 2 (Reuters) – CVS Health Corp (CVS.N)Walgreens Boots Alliance Inc. (WBA.O) and Walmart Inc. (WMT.N) agreed to pay approximately $13.8 billion to resolve thousands of lawsuits filed by U.S. state, local and tribal governments accusing drugstore chains of mishandling opioid painkillers. CVS said Wednesday it agreed to pay about $5 billion over 10 years, …

CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims Read More »

U.S. officials order Nvidia to halt sales of top AI chips to China

Join now for FREE unlimited access to Reuters.com Register Aug 31 (Reuters) – Chip designer Nvidia Corp (NVDA.O) said on Wednesday that U.S. officials told him to stop exporting two leading computer chips for artificial intelligence work to China, a move that could cripple the ability of Chinese companies to do advanced work like reconnaissance …

U.S. officials order Nvidia to halt sales of top AI chips to China Read More »

Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine

Moderna’s logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration Join now for FREE unlimited access to Reuters.com Register Aug 26 (Reuters) – Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved …

Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine Read More »

Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval

Signage is seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Join now for FREE unlimited access to Reuters.com Register Aug 17 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved Bluebird Bio’s (BLUE.O) gene therapy for patients with a rare disease …

Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval Read More »